Search Immortality Topics:

Page 3«..2345..1020..»

Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of…

Posted: March 31, 2020 at 5:47 pm

DetailsCategory: DNA RNA and CellsPublished on Tuesday, 31 March 2020 10:51Hits: 312

CAMBRIDGE, MA & SAN FRANCISCO, CA, USA I March 30, 2020 IGeneration Bio and Vir Biotechnology (Nasdaq: VIR) today announced a collaborative research agreement to explore the potential for Generation Bios non-viral gene therapy platform to extend the impact and reach of Virs current or future human monoclonal antibodies (mAb) against SARS-CoV-2, the virus responsible for COVID-19. Generation Bios technology has the potential to deliver genetic information directly to cells without the use of adeno-associated viruses (AAV), in effect instructing the patients body to produce the antibody itself.

The companies believe that this technology, coupled with Virs potent neutralizing antibodies, has the potential to provide effective, long-lasting protection against SARS-CoV-2. Virs leading antibody was isolated from a SARS-CoV-1 recovered patient and potently neutralizes SARS-CoV-2. Vir believes that this approach can potentially provide broad and longer-lasting protection.

Together, we believe we can develop long-lasting therapies suitable for population-wide prevention and treatment, said Generation Bio President and CEO Geoff McDonough, M.D. We are moving with urgency to explore leveraging our platform to build protection against COVID-19 for the long term.

Generation Bios proprietary non-viral gene therapy platform is designed to enable production of target proteins from a patients own cells. This approach may allow the patient to maintain stable levels of antibody expression for years, providing continuous protection against the target virus. In addition, the companies intend to leverage Generation Bios scalable manufacturing process to potentially extend the reach of Virs monoclonal antibodies to a greater number of patients.

We are eager to bring our antibodies to patients as quickly as possible, and should they work, to make them available to as many patients as quickly as possible. We are excited to explore the potential of ceDNA in an infectious disease setting and our anti-SARS-CoV-2 program offers a way to do that, said George Scangos, Ph.D., CEO of Vir. Both companies are highly motivated to make meaningful contributions to stopping this disease and we look forward to a productive collaboration with Generation Bio.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The companys non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patients life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.

About Virs Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in the Democratic Republic of Congo), hepatitis B virus, influenza A, SARS-CoV-2, malaria, and others.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus, and tuberculosis. For more information, please visit

SOURCE: Generation Bio

See the original post:
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of...

Recommendation and review posted by G. Smith

In Other (Biopharma) News: Non-Coronavirus Stories this Week – BioSpace

Posted: March 31, 2020 at 5:47 pm

The pharmaceutical industry has thrown its might against the spread of COVID-19 as companies race to develop treatment options and potential vaccines. While those companies fight the pandemic, they continue to take aim at other diseases. The following is a roundup of some of this week's non-coronavirus biopharma news.

AstraZeneca Not only did AstraZeneca halt a Phase III trial for chronic kidney disease early due to overwhelming efficacy, the company also won approval for Imfinzi as a first-line treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide). The approval was based on positive results from the Phase III CASPIAN trial showing IMFINZI in combination with platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus the standard-of-care treatment alone. In the Imfinzi plus chemotherapy arm, the risk of death was reduced by 27% with median OS of 13 months versus 10.3 months for chemotherapy alone. Results also showed an increased confirmed objective response rate in the Imfinzi plus chemotherapy arm, 68% versus 58% respectively. The second experimental arm testing tremelimumab in combination with Imfinzi and chemotherapy read out but did not meet the primary endpoint. Details will be presented at a forthcoming medical meeting, AstraZeneca said.

Novartis Swiss pharma giant Novartis announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. Hyperlipidemia refers to the high level of lipids (fats, cholesterol, triglycerides), such as LDL-C, found in the blood that are either acquired or from genetic disorders3. LDL-C is the most readily modifiable risk factor for Atherosclerotic Cardiovascular Disease (ASCVD). The pooled analysis of the ORION-9, -10 and -11 Phase III trials showed a durable and potent reduction in LDL-C of 51% when used in addition to other lipid-lowering therapies (LLT) over 17 months of treatment. Inclisiran is currently under review by the FDA and European Medicines Agency for use in adults with ASCVD or heterozygous familial hypercholesterolemia (HeFH) who have elevated LDL-C while being on a maximum tolerated dose of a LLT. If approved, inclisiran will be the first and only LDL-C-lowering treatment in the siRNA class, Novartis said. Additionally, a prespecified exploratory analysis using the safety reporting from all three trials indicated fewer MACE (major adverse cardiovascular events) with inclisiran compared to placebo. The overall safety and tolerability profile was generally similar between the inclisiran and placebo groups, the company said.

ElevateBio Less than one year after it launched, Cambridge, Mass.-based ElevateBio, an incubator focused on the development of startup cell and gene therapy companies, secured $170 million in a Series B financing round that will be used to support the companys next phase of growth. The Series B proceeds will enable ElevateBio to be fully operational with cGMP manufacturing and advance clinical development of at least six cell and gene therapies from across its portfolio companies to enter clinical studies this year and into 2021. The financing round was supported by the Invus Group, Surveyor Capital, EDBI and Vertex Ventures F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, and Samsara BioCapital. ElevateBio launched in May 2019 with $150 million in financing.

Jazz Pharmaceuticals The FDA accepted Jazz Pharmaceuticals New Drug Application for sleep disorder drug JZP-258 under priority review. Jazz is developing JZP-258 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. JZP-258 is a novel oxybate product candidate that has less sodium than Xyrem (sodium oxybate). Low sodium is crucial due to narcolepsys association with an increased risk of comorbid conditions, including hypertension and cardiovascular disease. Xyrem is the only available product approved to treat both cataplexy and EDS in patients with narcolepsy ages 7 years and older and is the standard of care for treatment of cataplexy. The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is July 21. Jazz presented the late-stage data of the Phase III study in September at World Sleep 2019 in Vancouver.

ZOLL Medical The FDA approved Zoll Medical Corporations second-generation TherOx System, which provides SuperSaturated Oxygen (SSO2) Therapy and reduces heart muscle damage in widow maker heart attack patients. SSO2 Therapy delivers hyperbaric levels of oxygen directly to the damaged heart muscle immediately after successful revascularization via angioplasty and stenting of the blocked coronary artery. It is indicated for patients who suffer the most serious kind of heart attack. SSO2 Therapy is the first and only FDA-approved treatment beyond percutaneous coronary intervention (PCI) to reduce muscle damage in heart attack patients, Zoll said in a statement.

Akron Florida-based Akron Biotech announced its expansion to a second manufacturing facility in the United States. Akron acquired a state-of-the-art 60,000-square-foot biologics manufacturing site in Sarasota, Florida. The new site bolsters the companys U.S. capacity and strengthening its position as the industrys premier ancillary materials supplier. The site will be operational later this year, the company said. The new site will facilitate rapid growth in each of the companys three main cGMP business verticals: cytokines and growth factors, growth and cryopreservation media, and viral inactivated human-derived media supplements, the company said. Akron will continue to manufacture its flagship cytokine product portfolio (IL-2, IL-7, IL-15, IL-21, and others) at large scale and under cGMP compliance at its pharmaceutical manufacturing facility overseas.

Nuvo Group Israels Nuvo Group received clearance from the FDA to market INVU, prescription-initiated, protocol-driven remote monitoring platform that offers measurements of fetal and maternal heart rate via a wireless sensor band. The INVU platform will be available by prescription from a healthcare provider who will initiate and schedule remote monitoring sessions.

See the original post:
In Other (Biopharma) News: Non-Coronavirus Stories this Week - BioSpace

Recommendation and review posted by G. Smith

Gene Therapy Market Companies Outlook and Trends Likely to Witness CAGR of 33.1% from 2019 to 2030 – Press Release – Digital Journal

Posted: March 31, 2020 at 5:47 pm

Gene Therapy Market industry development trends and strategic plan for positive Growth discuss in research report.The global gene therapy market is estimated to be over US$ 411.2 Mn in 2018. It is anticipated to grow at a double-digit CAGR of 33.1% from 2019 to 2030.

This press release was orginally distributed by SBWire

New York, NY -- (SBWIRE) -- 03/31/2020 -- As per research findings of Market Industry Reports (MIR), increasing number of product approvals & R&D activities, supportive government initiatives in the gene therapy arena are set to open new avenues for stakeholders.

Major Players Include:

The global gene therapy market is largely governed by prominent players such as Novartis AG, UniQure N.V., Regenxbio Inc., Sibiono GeneTech Co. Ltd., Amgen Inc., Voyager Therapeutics, Sarepta Therapeutics, Inc., Spark Therapeutics, Inc., Audentes Therapeutics, and Orchard Therapeutics plc, among others.

Get Access to Sample Pages @

Growth Factors:

Growth opportunities in the global gene therapy market looks promising during the forecast period. Rising incidences of chronic diseases as well as genetic disorders globally, favorable initiatives from governments to support research & development of gene therapy products and technological advancements are some of the key factors driving the global gene therapy market.

Similarly, increased focus of players in this market for getting approvals for gene therapy products is anticipated to boost the gene therapy market significantly during the forecast period. For instance, in May 2019, AveXis, a U.S.-based company received FDA's approval for Zolgensma. Zolgensma is used for the treatment of a rare genetic disorder and Spinal Muscular Atrophy (SMA) in pediatric patients below the age of 2 years."Companies are striving to discover, develop, and deliver gene therapies for rare genetic disorders,"

From a regional perspective, Europe is expected to witness the highest CAGR in the coming years due to presence of several gene therapy products in the development stage. Whereas, North America accounts for the largest share in the gene therapy market. The large share of this region can be attributed to rising incidences of chronic diseases & genetic disorders such as cancer, hemophilia, Multiple Sclerosis (MS), and others.

For deep-rooted insights on this topic, Go for Interesting Discount @


By Vector Type

Viral VectorsAdenovirusLentivirusRetrovirusAdeno-associated virusHerpes simplex virusPoxvirusVaccinia virusOthersNon-viral VectorsNaked plasmid vectorGene gunElectroporationLipofectionOthers

By Gene TypeAntigenCytokineTumor SuppressorSuicideDeficiencyGrowth FactorsReceptorsOthers

By ApplicationOncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious DiseasesOther Diseases


Deep-rooted quantitative and qualitative insights at segment & sub-segment levelGlobal insights with country levels informationComprehensive insights on market dynamics, and business environment Insights on 'Key Strategies' followed by leading players of the marketAccess to 'Latest Strategic Developments' registered by leading players of the market


Key Distributors ListFree addition of 'Company Profiles'Clientele Base Assessment

Byy Full Report Now @

About Market Industry ReportsMarket Industry Reports is a global leader in market measurement and advisory services. It is a 100% subsidiary of ExlTech. The firm has always been at the forefront of innovations to address worldwide industry trends and opportunities. We offer our clients a unique depth of market intelligence in an actionable format to move their business forward. Our analysis incorporates consumer study in more than 100 countries, providing a tactical approach to drive sustained business growth. We continue to pioneer state-of-the-art approach in research & analysis that will help you to overcome complexities and stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence, we unfold contingencies for our clients in the evolving world of technology, mega-trends, and industry convergence. We inspire our clients to empower and shape their businesses and to build world-class products.


2nd Floor, Manikchand Ikon,B-Wing, Dhole Patil Road,Sangamwadi, Pune 411 001Maharashtra, +1 347 767 5477 ( US ) +44 131 463 4161 ( UK ) + 91 8956 767 535 ( IN

For more information on this press release visit:

Read the original:
Gene Therapy Market Companies Outlook and Trends Likely to Witness CAGR of 33.1% from 2019 to 2030 - Press Release - Digital Journal

Recommendation and review posted by G. Smith

EMA grants conditional marketing authorisation in EU for gene therapy Zolgensma – Express Healthcare

Posted: March 31, 2020 at 5:47 pm

To treat babies, young children with spinal muscular atrophy

EMA has recommended granting a conditional marketing authorisation in the European Union for the gene therapy Zolgensma (onasemnogene abeparvovec) to treat babies and young children with spinal muscular atrophy (SMA), a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement.

There are currently limited treatment options for children with SMA in the EU. Patients also receive physical aids to support muscular functions and help them and their families cope with the symptoms of the disease.

Spinal muscular atrophy is usually diagnosed in the first year of life. Most patients with severe SMA do not survive early childhood. Patients with the disease cannot produce sufficient amounts of a protein called survival motor neuron (SMN), which is essential for the normal functioning and survival of motor neurons (nerves from the brain and spinal cord that control muscle movements). Without this protein, the motor neurons deteriorate and eventually die. This causes the muscles to fall into disuse, leading to muscle wasting (atrophy) and weakness.

The SMN protein is made by two genes, the SMN1 and SMN2 genes. Patients with spinal muscular atrophy lack the SMN1 gene but have the SMN2 gene, which mostly produces a short SMN protein that cannot work properly on its own. A one-time intravenous administration of Zolgensma supplies a fully functioning copy of the human SMN1 geneenabling the body to produce enough SMN protein. This is expected to improve their muscle function, movement and survival of children with the disease.

Treatment with Zolgensma should only be administered once in suitable clinical centres under the supervision of a physician experienced in the management of patients with SMA.

EMAs recommendation for conditional marketing authorisation is based on the preliminary results of one completed clinical trial and three supporting studies in patients with spinal muscular atrophy with different stages of disease severity. These included genetically diagnosed and pre-symptomatic patients.

The clinical trial providing the main body of data for the assessment of Zolgensma was conducted in 22 patients who were less than six months of age at the time of the gene replacement therapy with Zolgensma. The trial assessed the percentage of patients who had improvement in their survival (i.e. without the need to be permanently on a ventilator) and motor milestones, such as head control, crawling, sitting, standing and walking (with or without assistance).

The survival of patients treated with Zolgensma exceeded what can be expected from untreated patients with severe SMA. Out of 22 patients enrolled in the trial, 20 patients (91 per cent) were alive and did not need permanent ventilatory support at 14 months of age. The experience with this disease shows that at 14 months of age only 25 per cent of patients are still alive. These patients also achieved motor milestones, which are usually not achieved in the natural history of the disease. 14 patients (64 per cent) reached the milestone of independent sitting before 18 months of age. One patient (4 per cent) reached the milestone of walking unassisted before reaching 16 months of age. Patients with less motor deterioration appeared to benefit the most from the treatment with Zolgensma.

The most common side effects found in participants in the clinical trials for Zolgensma wereincreases in liver enzymes (transaminases) seen in blood tests. This is an effect of the immune response to the treatment.

Because Zolgensma is an advanced-therapy medicinal product (ATMP), it was assessed by the Committee for Advanced Therapies (CAT), EMAs expert committee for cell- and gene-based medicines.

On the basis of the CATs assessment and positive opinion, EMAs committee for human medicines (CHMP) recommended a conditional approval for this medicine. This is one of the EUs regulatory mechanisms to facilitate early access to medicines that fulfil an unmet medical need. This type of approval allows the Agency to recommend a medicine for marketing authorisation with less complete data than normally expected, in cases where the benefit of a medicines immediate availability to patients outweighs the risk inherent in the fact that not all the data are yet available.

Additional efficacy and safety data are being collected through three ongoing studies, a long-term registry and further investigations on the product, including recommendations for future quality development. All results must be included in post-marketing safety reports, which are continuously reviewed by EMA.

The opinion adopted by the CHMP is an intermediary step on Zolgensmas path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation.Once amarketing authorisationhas been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.

Read more from the original source:
EMA grants conditional marketing authorisation in EU for gene therapy Zolgensma - Express Healthcare

Recommendation and review posted by G. Smith

Gene Therapy Market Regulations and Competitive Landscape Outlook size 2027 – Skyline Gazette

Posted: March 31, 2020 at 5:47 pm

Report Description

A recent market intelligence report that is published by Data Insights Partner onGene Therapy marketmakes an offering of in-depth analysis of segments and sub-segments in the regional and international Gene Therapy market. The research also emphasizes on the impact of restraints, drivers, and macro indicators on the regional and world Gene Therapy market over the short as well as long period of time. A detailed presentation of forecast, trends, and dollar values of international Gene Therapy market is offered. In accordance with the report, the global Gene Therapy market is projected to expand at a CAGR of 30% over the period of forecast.

Market Insight, Drivers, Restraints& Opportunity of the Market:

Gene therapy is a medical procedure which replaces defective genes or introduces new genes n order to prevent or cure genetic disorders. This procedure has become a bench mark in medical industry as there is no requirement of surgery or drugs or other procedure which has side effects on the individuals. Gene therapy was first commercialized in China in 2004 by China based SiBono Gene Tech (product Gendicine).

The global gene therapy market has been expanding due to the rigorous research conducted in the field of genetics. The rising awareness about the capability of cure of several rare genetic diseases by gene therapy is another important driver which leads the global gene therapy market during the forecast period. Gene therapy has capability cure several life threatening diseases such as cancer, cardiac diseases, AIDS, cystic fibrosis, age-related disorders, sickle cell anemia etc. In March 2019, the director of the National Health Institute (NIH), the U.S. announced that the recent clinical trials on the gene therapy for the treatment of sickle cell anemia showed promising result- therefore, increasing prevalence of aforementioned lie threatening diseases would likely to drive the growth of the global gene therapy market during the forecast period.

Request for Report Sample:

On the other hand, treatment cost and stringent regulatory conditions etc. may hamper the growth of the global gene therapy market in the upcoming future. The results of Gendicine clinical trials were published in 2003 and the medicine got approval by the China State Food and Drug Administration in the same year. Although approved in China, Gendicines use is not very promising outside China. There are several concerns among the researchers about the quality of the clinical trials performed and safety and efficacy of the treatment. However, Gendicines equivalent Advexin (company Introgen Therapueitcs) is still waiting for the FDA approval.

Increasing investment to the gene therapy related research (around 10 Bn was invested in 2015 by private and public organizations), new product developments such as (Zolgensma in 2019), strategic alliance among the key players (such as collaboration between Axovant and Yposkesi) would bring the global gene therapy market an opportunity to propel during the forecast period. In May 2019, Avexis (a Novartis company) has got the FDA approval for Zolgensma for treatment of spinal muscular atrophy for the pediatric patients (less than 2 years of age).

Segment Covered:

This market intelligence report on the global gene therapy market encompasses market segments based on product, application, target user and geography. On the basis of product, the sub-markets is segmented into Yescarta, Kymriah, Strimvelis, Gendicine, Zolgensma and others (Advexin). Based on application, the global gene therapy market has been segregated into large B-Cell lymphoma, Car T Cell therapy, ADA-SCID (adenosine deaminase deficiency), muscular atrophy, head and neck squamus cell carcinoma, others (Crigler-Najjar syndrome). By target user, the global gene therapy market is also classified into adult and pediatric. By Geography, the global gene therapy market has been divided into North America (the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other countries), Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries), Asia Pacific (India, Japan, China, Australia and New Zealand and other countries), Middle East and Africa (GCC, South Africa, Israel and Other countries).

Profiling of Market Players:

This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as Novartis, Gilead Sciences, Orchard Therapeutics Ltd, SiBiono GeneTech Co, Introgen Therapeutics and among others have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as gene therapy market related investment & spending and developments by major players of the market are tracked in this global report.

Report Highlights:

In-depth analysis of the micro and macro indicators, market trends, and forecasts of demand is offered by this business intelligence report. Furthermore, the report offers a vivid picture of the factors that are steering and restraining the growth of this market across all geographical segments. In addition to that, IGR-Growth Matrix analysis is also provided in the report so as to share insight of the investment areas that new or existing market players can take into consideration. Various analytical tools such as DRO analysis, Porters five forces analysis has been used in this report to present a clear picture of the market. The study focuses on the present market trends and provides market forecast from the year 2017-2027. Emerging trends that would shape the market demand in the years to come have been highlighted in this report. A competitive analysis in each of the geographical segments gives an insight into market share of the global players.

Request for Report Analysis:

Salient Features:

This study offers comprehensive yet detailed analysis of the Gene Therapy market, size of the market (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the period of forecast: 2019 2027, taking into account 2017 as the base year

It explains upcoming revenue opportunities across various market segments and attractive matrix of investment proposition for the said market

This market intelligence report also offers pivotal insights about various market opportunities, restraints, drivers, launch of new products, competitive market strategies of leading market players, emerging market trends, and regional outlook

Profiling of key market players in the world Gene Therapy market is done by taking into account various parameters such as company strategies, distribution strategies, product portfolio, financial performance, key developments, geographical presence, and company overview

Leading market players covered this report comprise names such as. Novartis, Gilead Sciences, Orchard Therapeutics Ltd, SiBiono GeneTech Co, Introgen Therapeutics and among others

The data of this report would allow management authorities and marketers of companies alike to take informed decision when it comes to launch of products, government initiatives, marketing tactics and expansion, and technical up gradation

The world market for Gene Therapy market caters to the needs of various stakeholders pertaining to this industry, namely suppliers, manufacturers, investors, and distributors for Gene Therapy market. The research also caters to the rising needs of consulting and research firms, financial analysts, and new market entrants

Research methodologies that have been adopted for the purpose of this study have been clearly elaborated so as to facilitate better understanding of the reports

Reports have been made based on the guidelines as mandated by General Data Protection Regulation

Ample number of examples and case studies have been taken into consideration before coming to a conclusion

Reasons to buy:

vIdentify opportunities and plan strategies by having a strong understanding of the investment opportunities in the Gene Therapy market

vIdentification of key factors driving investment opportunities in the Gene Therapy market

vFacilitate decision-making based on strong historic and forecast data

vPosition yourself to gain the maximum advantage of the industrys growth potential

vDevelop strategies based on the latest regulatory events

vIdentify key partners and business development avenues

vRespond to your competitors business structure, strategy and prospects

Read the original post:
Gene Therapy Market Regulations and Competitive Landscape Outlook size 2027 - Skyline Gazette

Recommendation and review posted by G. Smith

The Global Cryogenic Tanks Market is expected to grow by USD 393.99 mn during 2020-2024, progressing at a CAGR of 7% during the forecast period -…

Posted: March 31, 2020 at 5:45 pm

NEW YORK, March 30, 2020 /PRNewswire/ --

Global Cryogenic Tanks Market 2020-2024 The analyst has been monitoring the global cryogenic tanks market and it is poised to grow by USD 393.99 mn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on global cryogenic tanks market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Read the full report:

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increased demand for nitrogen from food processing industry. In addition, growing brewery industry in APAC is anticipated to boost the growth of the global cryogenic tanks market as well.

Market Segmentation The global cryogenic tanks market is segmented as below: Product: LNG Nitrogen Others

Geographic Segmentation: North America APAC Europe South America MEA

Key Trends for global cryogenic tanks market growth This study identifies growing brewery industry in APAC as the prime reasons driving the global cryogenic tanks market growth during the next few years.

Prominent vendors in global cryogenic tanks market We provide a detailed analysis of around 25 vendors operating in the global cryogenic tanks market 2020-2024, including some of the vendors such as Air Products and Chemicals Inc., Air Water Inc., Chart Industries Inc., Cryofab Inc., FIBA Technologies Inc., INOX India Pvt. Ltd., L Air Liquide SA, Linde AG, VRV Srl and Wessington Cryogenics . The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Read the full report:

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

Excerpt from:
The Global Cryogenic Tanks Market is expected to grow by USD 393.99 mn during 2020-2024, progressing at a CAGR of 7% during the forecast period -...

Recommendation and review posted by G. Smith

Page 3«..2345..1020..»